# Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

> **NCT03277183** · PHASE4 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 5 (actual)

## Conditions studied

- Anemia
- CKD
- Atherosclerosis
- Cardiovascular

## Interventions

- **DRUG:** Low dose erythropoietin
- **DRUG:** High dose erythropoietin

## Key facts

- **NCT ID:** NCT03277183
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-02
- **Primary completion:** 2019-06-03
- **Final completion:** 2019-06-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277183, "Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03277183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*